The word according to Fred
And Fred said, let there be sequence: and there were sequencers.
19
02, 2025
13
02, 2025
Roche emerges from the Lazarus pit
Is Roche going to “knock it out of the park” or “jump the shark”? Everyone I know is excited, even if many of them are sceptical, about the Feb 20th webinar and what we will learn about SBX. Alex Dickinson appears to be driving most of the buzz, […]
24
01, 2025
cfTAPS: a new method for cfDNA epigenomes
A new study introduces a sensitive and cost-effective method for MCED and diagnostic using multimodal cfTAPS, enhancing the potential of liquid biopsies. In this post I’ll take a dive into the new paper, lay out a short overview of DNAme-mod methods development, and the possible […]
13
01, 2025
Proteomics. Proteomics. Proteomics.
What does UK Biobank’s Pharma Proteomics election of Olink + Ultima Genomics NGS mean for proteomics researchers, and for the wider genomics community? Does it create a new Olink monopoly on NGS-proteommics? And what’s the impact on NGS technology providers? At the end of last […]
19
04, 2024
@tagomics epigenomic profiling of non-methylated CpG’s
A new company, Tagomics, have a very interesting pre-print: Epigenomic profiling of active regulatory elements by enrichment of unmodified CpG dinucleotides that describes their novel epigenomic profiling approach called “Active-Seq”, a bisulfite-free method designed to enrich unmethylated DNA as opposed to enriching methylated (e.g. MeDIP, GH) or everything […]
15
03, 2024
2024 @novonordiskfond prize to Solexa: This is why we need a pub at Addenbrookes
NGS would not exist without the important discussions at The Panton Arms where Illumina Next-Generation sequencing was invented…sort of. Professors Sir David Klenerman and Sir Shankar Balasubramanian are being honoured with the 2024 Novo Nordisk Prize for their pioneering work on Solexa sequencing. This led to the $1000 […]
21
02, 2024
Pushing past current sensitivity limits in liquid biopsy
Current liquid biopsy diagnostics, and novel uses such as MRD and Molecular Response analysis, are limited by the amount of ctDNA in a typical patients plasma. ctDNA levels vary across indications (Bettegowda 2014) and generally increase with disease stage. ctDNA is released by tumor cell turnover […]
17
08, 2023
Mathias Mann Makes Multiomics Mega
Apparently you can do Proteomics from Qiagen AllPrep: in In depth profiling of the cancer proteome from the flowthrough of standard RNA-preparation kits for precision oncology, from Mathias Mann’s Proteomics group in Denmark, the authors presents their modifications to Qiagen’s AllPrep (DNA, RNA and protein) […]
6
03, 2023
#AGBT’23: Illumina
Continuing with my summary of what happened at #AGBT23 here’s my round up of the big announcements from Illumina. Of course whilst much of the data presented at the meeting was generated on an Illumina sequencer there was a very significant amount of non-Illumina data […]
23
02, 2023
@illumina came out fighting at JPM’22 with short and long punches – but I forgot to hit “post”!
Sorry this one is over a year late – but I needed to link to it for my more recent AGBT post!James Illumina has been hugely successful in developing SBS chemistry but their lack of competition in short-read sequencing is being challenged by long-term players […]
